Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04324450
Other study ID # C19-17
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 12, 2020
Est. completion date February 9, 2023

Study information

Verified date April 2021
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact Anne LAPRIE, MD
Phone +33(0)562746164
Email laprie.anne@iuct-oncopole.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Brain tumours are the leading cause of cancer-related death and morbidity in children, adolescents and young adults. The brain is also one of the most sensitive organs to treatments used in pediatric oncology, even for cancers not related to the central nervous system. Therapeutic index is therefore a major issue in pediatric neuro-oncology. The efficacy of the therapy as well as its toxicity are difficult to measure using standard tests. In order to optimize therapies that could have an impact on the brain, and consequently on the quality of life of patients, it becomes crucial to optimize the means of evaluation. Few studies to date have focused on the various components of memory impacted following treatment of a posterior fossa tumour. However, supra-tentorial structures such as the hippocampus, which have long been described for their role in memory, are either partially irradiated (irradiated in their lower part due to their proximity to the target volume during irradiation of the posterior fossa) or completely irradiated (e.g. included in the prophylactic irradiation of medulloblastoma prior to dose supplementation in the posterior fossa). On the other hand, the cerebellum plays a central role in learning and procedural memory involved in motor and cognitive learning, as it enables automation and procedural retention such as reading (automation of the grapho-phonemic conversion procedure) or arithmetic (mental arithmetic). IMPALA study is aimed at investigating the impact of different irradiation doses received by children treated with radiotherapy on cognitive functions related to the hippocampus and to the cerebellum. This exploratory study will thus provide elements enabling a better limitation of radiotherapy doses on regions linked to the development of cognition and memory. The project brings together researchers and clinicians with complementary expertise in oncology, neurology and imaging in both children and adults. This study will also provide a better understanding of the role of the cerebellum in memory and executive functions, and develop a method that can then be used in a prospective longitudinal multicentre form.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date February 9, 2023
Est. primary completion date September 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: FOR ALL PARTICIPANTS - Affiliation to or beneficiary of a social security scheme - French mother tongue - Sufficient visual, auditory (hearing aids permitted), speaking and writing skills for proper performance of neuropsychological tests - Written informed consent of the adult participant, or of the representatives of parental authority, if applicable FOR IRRADIATED PATIENTS - Patient treated before 18 years old - Patient considered cured after irradiation of a brain tumour (complete clinical and iconographic response at 5 years after the end of radiotherapy). - Patient who has received localized brain irradiation or craniospinal irradiation for a brain tumour whose treatment includes first-line radiotherapy (ependymomas, medulloblastomas, malignant germinal tumours) - Patient who received 54 or 59.4 Gy in a localized part of the posterior fossa or supra-tentorial brain; or patients who received 54 Gy over all or part of the posterior fossa and prophylactic irradiation of the entire brain FOR PATIENTS TREATED BY SURGERY AND/OR CHEMOTHERAPY - Patients resected from a posterior fossa tumour without radiotherapy (i.e., brain tumours whose treatment does not include first-line radiotherapy: low-grade gliomas including pilocytic astrocytomas) - Patient treated before 18 years old - Patient considered cured at 5 years after the end of treatment Exclusion Criteria: FOR ALL PARTICIPANTS - Individual under legal protection of adults (judicial safeguard, guardianship, curatorship, institutionalized, or under a mandate for future protection) - Severe ataxia - Individual who participated in another research study that included treatment within the previous 3 years - Individual with a contraindication to MRI (i.e. in particular, cardiac pacemaker or defibrillator carriers, implanted equipment activated by an electrical, magnetic or mechanical system, carriers of haemostatic clips on intracerebral aneurysms, carriers of orthopaedic implants, claustrophobic) FOR HEALTHY VOLUNTEERS - Known neurological or psychiatric history - History of learning disability or neurodevelopmental disorder follow-up - Patients undergoing psychotropic treatment (methylphenidate, antidepressants, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MRI
The MRI protocol is composed of: T1-weighted anatomical sequences DTI sequences resting functional MRI 3D MR spectroscopic imaging
Behavioral:
Cognitive assessment
Battery of neuropsychological tests

Locations

Country Name City State
France ToNIC / UMR1214 Toulouse

Sponsors (1)

Lead Sponsor Collaborator
Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Structural characteristics of declarative memory neuronal substrate: volume of the hippocampus Volume of the hippocampus obtained from T1-weighted anatomical Day 1
Primary Structural characteristics of declarative memory neuronal substrate: cortical thickness of the hippocampus Cortical thickness of the hippocampus obtained from T1-weighted anatomical Day 1
Primary Structural characteristics of declarative memory neuronal substrate: Microstructural integrity of the hippocampus Microstructural integrity of the hippocampus obtained from Diffusion Tensor Imaging (DTI) sequences used to calculate the fraction of anisotropy and the mean diffusion sequences Day 1
Primary Episodic memory performance Episodic memory performance of the participants in the different groups when evaluating episodic declarative memory, assessed with Children's Memory Scale in participants under 16 years old and with Wechsler Memory Scale MEM-III in participants over 16 years old (Day 2) Day 2
Secondary Declarative episodic memory assessment scores Scores obtained at memory clinical scale for children Day 2
Secondary Declarative semantic memory assessment scores Scores obtained at Wechsler Intelligence Scale for Children Day 2
Secondary Procedural memory assessment scores Scores obtained at Serial Reaction Time Task Day 2
Secondary Short-term auditive memory assessment scores Scores obtained at Wechsler Intelligence Scale for Children Day 2
Secondary Short-term visual memory assessment scores Scores obtained at Wechsler Memory Scale Day 2
Secondary Intellectual capacities assessment scores Scores obtained at Wechsler Intelligence Scale for Children Day 2
Secondary Language assessment scores Scores obtained at Peabody Picture Vocabulary Test Day 2
Secondary Motor functions assessment scores Scores obtained at Purdue Pegboard Test Day 2
Secondary Executive functions assessment scores Scores obtained at TMT A and B, Stroop Test and Wisconsin Card Sorting Test Day 2
Secondary Attentional capacities assessment scores Scores obtained at Test of Attentional Performance 2.3.1 Day 2
Secondary Cerebellar volume Cerebellar volume obtained from T1-weighted anatomical sequences Day 1
Secondary Micro-structural integrity of the cerebellum Micro-structural integrity of the cerebellum achieved by using DTI sequences to calculate the fraction of anisotropy and average diffusivity Day 1
Secondary Cerebral blood volume obtained from brain perfusion imaging Cerebral blood volume obtained from brain perfusion imaging Day 1
Secondary Post-therapeutic hypoxia Post-therapeutic hypoxia as measured by magnetic resonance spectrometry of the hippocampus and cerebellum Day 1
Secondary Neuronal density Neuronal density as measured by magnetic resonance spectrometry of the hippocampus and cerebellum Day 1
Secondary Functional connectivity index Functional connectivity index, obtained via resting functional MRI. Day 1
Secondary Age at the time of treatment Age at the time of treatment from the patients' medical records Day 1
Secondary Radiotherapy doses Radiotherapy doses received in the cerebellum, in the hippocampus, and in the whole brain from the patients' medical records Day 1
Secondary Cerebellum and hippocampus Normal Tissue Complication Probability Cerebellum and hippocampus Normal Tissue Complication Probability (NTCP) Day 1
See also
  Status Clinical Trial Phase
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Not yet recruiting NCT06335745 - PediCARE Health Equity Intervention in High-Risk Neuroblastoma N/A
Withdrawn NCT04719416 - Relaxation Therapy in Pediatric Oncology N/A
Completed NCT01645436 - Physical Activity in Pediatric Cancer (PAPEC) N/A
Completed NCT04409301 - Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation N/A
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05425043 - Granulocyte Transfusions After Umbilical Cord Blood Transplant N/A
Recruiting NCT05071859 - Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
Recruiting NCT03241251 - Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
Recruiting NCT05384288 - Response to Influenza Vaccination in Pediatric Oncology Patients
Completed NCT04586491 - The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients N/A
Recruiting NCT05569512 - Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Phase 1/Phase 2
Enrolling by invitation NCT05294380 - Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
Completed NCT02665819 - Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility. N/A
Completed NCT02675166 - Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
Not yet recruiting NCT05454163 - Post-radiotherapy Rhinosinusitis in Children
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Withdrawn NCT01828502 - Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer Phase 2
Completed NCT02032121 - Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors N/A
Completed NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Phase 1